Keyword: U.S. Department of Justice
Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.
Mallinckrodt is getting burned on all sides for its marketing and price hikes for H.P. Achtar Gel. Now, a major U.S. insurer wants to pile on.
Teva’s $519 million settlement with the U.S. government in 2016 was meant to clear its name. Now, former leaders will foot their end of the bargain.
Acadia’s Nuplazid is under the gun after prosecutors launched a marketing probe in March. Now the drug has to cope with a trial flop in schizophrenia.
For just the second time, the DOJ indicted an opioid distributor for its role in illegally pushing pills at the height of the addiction epidemic.
Sanofi's Bioverativ buy buoyed its rare disease lineup. But for a Swiss man, the deal allegedly brought some illegal gains—and a U.S. criminal case.
Novartis and the feds are close to settling a kickback lawsuit, according to an attorney's letter posted publicly by mistake—and then quickly removed.
When Insys settled with the feds for $225 million, the drugmaker hoped it had put its troubled past behind it. Now they’re filing for bankruptcy.
Chafing under federal kickback charges tied to its H.P. Acthar Gel, Mallinckrodt appeared to be clear with a settlement in the works. Not so fast.
Bad news for Mallinckrodt: Federal prosecutors will join plaintiffs in whistleblower suits alleging illegal marketing of Questcor's H.P. Acthar Gel.